NRx's Pivot: From Bipolar Pill to DARPA Trials and a 'Fossil Virus' ALS Therapy
Preservative-free ketamine clears its final ANDA hurdle while NRX-101 gains a military-funded platform and GeNeuro grafts on a potential first-in-class ALS franchise.
NRXP · Earnings Call · 2026-08-17
One deficiency left—and it's a plastic prong
The quarter opened with the story long-suffering investors had been waiting for reaching its endgame. The ANDA for preservative-free ketamine is down to a single open item: the Luer-lock cap on the vial. Javitt framed the period as “a major inflection point for our company across multiple key objectives” — Jonathan Javitt, CEO · 2026-08-17, and the regulatory detail shows how far the review has come:The company has since ordered 5 million units of launch stock—consistent with the blow-fill-seal manufacturing capacity it has discussed since 2025—and pegged the existing market at “a $750 million current market of ketamine” — Jonathan Javitt, CEO · 2026-08-17. That milestone now rests alongside the branded NRX-100 NDA, targeted for 2027 using real-world evidence from 65,000 patients, backed by both a presidential executive order and congressional appropriations language steering the FDA toward RWE.The FDA identified no major deficiencies related to the drug or with manufacturer. A single major deficiency was identified, however, related to the Luer lock component of the vial... This attestation has been provided to the FDA and the company aims for 2026 approval.
SPARC-TMS: a military weapon for NRX-101
The bigger news is the strategic reinvention of NRX-101. For years the D-cycloserine/lurasidone combination was a suicide-bipolar drug that failed its primary antidepressant endpoint—the company itself acknowledged in mid-2025 that it “did not demonstrate that NRX-101 is a superior antidepressant to a very well-established antidepressant namely lurasidone” — Jonathan C. Javitt, Chief Executive Officer · 2025-08-20. Now it is being repositioned entirely around neuroplasticity. The SPARC-TMS trial pairs NRX-101 with robotic TMS, fields 240 patients in HOPE clinics plus 160 at military treatment facilities, and—critically—is funded by the Department of Defense. As Javitt described it in Q&A, “if this trial gets funded... a kind of massive nondilutive funding that rarely happens” — Jonathan Javitt, CEO · 2026-08-17. Military personnel on chronic antidepressants are not deployable; a pilot on SSRIs is grounded for five years, making the combination a force-readiness priority. That expands NRX-101's addressable population from a niche inpatient market to over 15 million treatment-resistant American adults. This is genuinely new—prior calls referenced transcranial magnetic stimulation and Dr. Brown's ONE-D protocol, but never a DARPA prime-contractor role. Notably, Javitt cited evidence that “ketamine plus TMS actually decreases the effectiveness of TMS” — Jonathan Javitt, Chief Executive Officer · 2025-11-17, framing NRX-101 as the better neuroplastic partner.GeNeuro: trading a septic tank for a 'fossil virus' cure
The most striking addition, however, is GeNeuro. The acquisition—finalized in June by the Swiss courts—brings two clinical-stage monoclonal antibodies targeting human endogenous retroviruses: GNK-301 against the HERV-K envelope protein in sporadic ALS, and temelimab against the HERV-W envelope protein in multiple sclerosis, type 1 diabetes, and possibly psychosis.This reframes the entire portfolio around a bold biological idea: that 8% of the human genome is "fossilized viruses" whose envelope proteins are "exquisitely neurotoxic," neutralized by antibodies "like a sponge for spilled milk." The company's own keyword shift captures the pivot—HERV-W and the U.S. military now dominate, while "Lurasidone" and "Akathisia" are the biggest decliners. GeNeuro is partnered with NIH (the drug was co-invented by the head of NINDS ALS research, with a 3% royalty to NIH), has cleared the first round of a congressionally-directed medical research program, and targets first-in-human trials for July 2027. Javitt framed the funding as abundant: “ALS has a massive stream of available funding.” — Jonathan Javitt, CEO · 2026-08-17GeNeuro, a word that's new to many of you, is the culmination of 3 years of work and the potential beginning of a breathtaking paradigm-changing but longer-term opportunity.